Company Valuation: GlaxoSmithKline Pharmaceuticals Limited

Data adjusted to current consolidation scope
Fiscal Period: March 2022 2023 2024 2025 2026 2027 2028 2029
Market Cap 1 281,714 224,319 329,173 487,432 386,822 446,893 - -
Change - -20.37% 46.74% 48.08% -20.64% 15.53% - -
Enterprise Value (EV) 256,351 207,663 329,173 487,432 386,822 446,893 446,893 446,893
Change - -18.99% 58.51% 48.08% -20.64% 15.53% 0% 0%
P/E 16.6x 36.7x 55.8x 52.5x 37.3x 38x 33.3x 30.4x
PBR 10.6x 12.9x 18.5x 25x 17.1x 16.9x 14.3x 12.6x
PEG - -0.6x -16.49x 0.9x 3.2x 2.8x 2.4x 3.15x
Capitalization / Revenue 8.59x 6.9x 9.53x 13x 10.1x 10.3x 9.22x 8.43x
EV / Revenue 0x 0x 0x 0x 0x 10.3x 9.22x 8.43x
EV / EBITDA 0x 0x 0x 0x 0x 30.1x 26.3x 24.1x
EV / EBIT 0x 0x 0x 0x 0x 30.2x 26.3x 24.7x
EV / FCF 0x 0x 0x 0x 0x 37.2x 33.2x 29.6x
FCF Yield 2.75% 1.96% 1.67% 2.6% 2.19% 2.69% 3.01% 3.38%
Dividend per Share 2 30 32 32 42 57 29.5 29.5 35
Rate of return 1.8% 2.42% 1.65% 1.46% 2.5% 1.12% 1.12% 1.33%
EPS 2 100 36.05 34.83 54.76 61.15 69.37 79.15 86.8
Distribution rate 30% 88.8% 91.9% 76.7% 93.2% 42.5% 37.3% 40.3%
Net sales 1 32,780 32,517 34,537 37,492 38,217 43,335 48,469 52,982
EBITDA 1 8,273 8,043 9,087 11,774 13,092 14,838 16,983 18,562
EBIT 1 7,592 7,385 8,390 11,106 12,428 14,820 16,987 18,102
Net income 1 16,947 6,107 5,900 9,276 10,360 11,850 13,407 14,708
Net Debt -25,363 -16,656 - - - - - -
Reference price 2 1,662.95 1,324.15 1,943.10 2,877.30 2,283.40 2,638.00 2,638.00 2,638.00
Nbr of stocks (in thousands) 169,406 169,406 169,406 169,406 169,406 169,406 - -
Announcement Date 5/16/22 5/17/23 5/17/24 5/13/25 5/13/26 - - -
1INR in Million2INR
Estimates

P/E, Detailed evolution



P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
38.83x - - 1.1% 4.88B
41.43x14.03x29.73x0.48% 1,261B
40.79x6.85x19.26x1.91% 671B
37.33x8.57x17.72x2.36% 518B
21.83x5.29x13.24x2.47% 387B
101.76x5.82x24.8x2.37% 353B
23.99x5.78x14.05x2.75% 300B
23.93x4.79x13.46x1.83% 283B
23.64x7.27x13.36x2.2% 248B
-40.04x7.4x46.61x1.94% 211B
Average 31.35x 7.31x 21.36x 1.94% 424B
Weighted average by Cap. 36.56x 8.81x 22.37x 1.7%

Y-o-Y evolution of P/E

Valuation ratios - P/E - GlaxoSmithKline Pharmaceuticals Limited

Historical PBR trend

Valuation ratios - PBR - GlaxoSmithKline Pharmaceuticals Limited

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - GlaxoSmithKline Pharmaceuticals Limited

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - GlaxoSmithKline Pharmaceuticals Limited


Year-on-year evolution of the Yield

Valuation ratios - Yield - GlaxoSmithKline Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. GLAXO Stock
  4. Valuation GlaxoSmithKline Pharmaceuticals Limited